Role of FXR in Hepatitis C Virus Replication (GGST)

This study has been terminated.

Sponsor:

Information provided by (Responsible Party):

Hospices Civils de Lyon

ClinicalTrials.gov Identifier:

NCT01492998

First received: September 23, 2010

Last updated: December 14, 2011

Last verified: September 2010

History of Changes

Purpose

In vitro in the hepatitis C virus (HCV) replicon system, modulation of the biliary salts nuclear receptor FXR by either agonists or antagonists respectively increases or decreases the replication of HCV (J Hepatol, 2008, 48: 192-9). One antagonist of FXR is a vegetal sterol, guggulsterone, that is extracted from the Commiphora mukul tree and that has already been given safely to hyper cholesterolemic patients in a clinical trial (JAMA 2003, 290: 765-72). The aim of this trial is to test the effect of the FXR antagonist guggulsterone given orally, three times a day, on the viral load in 15 HCV genotype 1 chronically infected patients.

Condition	Intervention
Chronic Hepatitis C	Other: guggulsterone, a natural FXR antagonist.


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Study of the Role of the Biliary Salts Nuclear Receptor FXR in Hepatitis C Virus Replication

Resource links provided by NLM:

MedlinePlus related topics: Dietary Sodium Hepatitis Hepatitis A Hepatitis C

U.S. FDA Resources

Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:

Evolution of the HCV plasmatic viral load while taking the FXR inhibitor guggulsterone. [ Time Frame: One week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Modification of the fraction of the circulating viral forms associated with apolipoprotein B [ Time Frame: One week ] [ Designated as safety issue: No ]


Enrollment:	15
Study Start Date:	January 2010
Primary Completion Date:	March 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Guggulsterone One arm of 15 chronically HCV genotype one infected patients	Other: guggulsterone, a natural FXR antagonist. Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone

Eligibility


Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male patients infected by HCV genotype 1, with anti-HCV antibodies, non responders to at least one first line of therapy
Viral load > 1 x 105 UI/mL for more than 6 months and not treated for at least the last two months.
METAVIR score < F4

Exclusion Criteria:

Alcohol intake > 20 g/day
Immuno - suppressive therapy
Obesity BMI > 30, diabetes
Dyslipidemia requiring specific therapy
Liver cirrhosis or carcinoma
HIV or HBV co-infections
Other liver diseases
Major organ failures
Therapy with cytochrome P450 metabolized drugs

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01492998

Locations


France
Department of hepatology, Hospices Civils de Lyon, Hôtel Dieu
Lyon, France, 69288

Sponsors and Collaborators

Hospices Civils de Lyon

Investigators


Principal Investigator:	Christian Trépo, MD, Prof.	Hospices Civils de Lyon
Principal Investigator:	Marianne Maynard, MD	Hospices Civils de Lyon

More Information

No publications provided by Hospices Civils de Lyon

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Scholtes C, André P, Trépo C, Cornu C, Remontet L, Ecochard R, Bejan-Angoulvant T, Gueyffier F. Farnesoid X receptor targeting for hepatitis C: study protocol for a proof-of-concept trial. Therapie. 2012 Sep-Oct;67(5):423-7. doi: 10.2515/therapie/2012058. Epub 2012 Dec 18.


Responsible Party:	Hospices Civils de Lyon
ClinicalTrials.gov Identifier:	NCT01492998 History of Changes
Other Study ID Numbers:	2008.501-02
Study First Received:	September 23, 2010
Last Updated:	December 14, 2011
Health Authority:	France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Hospices Civils de Lyon:


Hepatitis C virus Biliary salts Farnesoid X receptor Guggulsterone

Additional relevant MeSH terms:


Hepatitis Hepatitis A Hepatitis C Digestive System Diseases Enterovirus Infections Flaviviridae Infections	Hepatitis, Viral, Human Liver Diseases Picornaviridae Infections RNA Virus Infections Virus Diseases

ClinicalTrials.gov processed this record on March 01, 2015

To Top